Table 1 Patient characteristics and outcomes of those who developed pulmonary cavitation
From: Pulmonary cavitation: an under-recognized late complication of severe COVID-19 lung disease
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age range | 50–59 | 40–49 | 60–69 | 40–49 | 60–69 | 50–59 | 40–49 | 30–39 | 40–49 | 50–59 | 30–39 | 40–49 |
| BMI | 30.9 | 30.4 | 31.3 | 29.2 | 25.1 | 29.4 | 26.3 | 21.5 | 30.1 | 19.8 | 24 | 27.7 |
| Comorbidities | DM, HT | HT | DM | DM | COPD | HT | HT | DM, HT | DM | DM | DM | |
| On admission | ||||||||||||
| Time from symptom onset to intubation (days) | 6 | 12 | 9 | 7 | 5 | 5 | 8 | 15 | 3 | 9 | 10 | 8 |
| P/F ratio | 48.8 | 41.6 | 49.7 | 33.0 | 46.1 | 47.0 | 65.3 | 41.8 | 70.5 | 100.1 | 109.4 | 104.5 |
| SOFA score (points) | 24 | 21 | 24 | 25 | 23 | 23 | 16 | 21 | 25 | 23 | 18 | 17 |
| Neutropenia | Y | |||||||||||
| Leucocytes (× 10 * 9/L) | 0.49 | 1.35 | 0.3 | 2.78 | 0.6 | 1.1 | 1.66 | 1.03 | 0.46 | 2.91 | 1.62 | 2.63 |
| During the admission | ||||||||||||
| NM blockade | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | ||
| VTE | DVT and PE | PE | DVT | DVT | ||||||||
| CVA | Y | Y | ||||||||||
| CRRT/IHD | Y | Y | Y | Y | Y | Y | Y | |||||
| ECMO | Y | Y | Y | |||||||||
| Proned | Y | Y | Y | Y | Y | Y | Y | Y | Y | |||
| Tracheostomy | Y | Y | Y | Y | Y | Y | Y | Y | ||||
| Days of systemic CS | 17 | 15 | 19 | 24 | 11 | 14 | 14 | 25 | 18 | 9 | 6 | 5 |
| + ve fungal cultures or serology | Y | Y | Y | Y | Y | |||||||
| Treated for fungal infection | Y | Y | Y | Y | Y | Y | Y | Y | ||||
| Duration of hospital stay (days) | 37 | 25 | 53 | 33 | 53 | 74 | 101 | 133 | 57 | 56 | 47 | 40 |
| Outcome | ||||||||||||
| Deceased | Deceased | Deceased | Deceased | Deceased | Deceased | Discharged home | Discharged home | Discharged home | Discharged home | Discharged home | Discharged home | |
